Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Medications and Management: The Treatment Strategy

At a Glance

The primary treatment for Parkinson's motor symptoms is Levodopa combined with Carbidopa, which replenishes dopamine. Doctors may also use dopamine agonists or MAO-B inhibitors. Managing treatment involves balancing symptom relief against side effects like dyskinesia and "wearing off."

Choosing the right medication strategy is a collaborative process between you and your neurologist. In the early years of Parkinson’s, the goal is often simple: provide enough dopamine to keep you moving and active while minimizing side effects.

The Gold Standard: Levodopa/Carbidopa

Levodopa remains the most effective treatment for managing the motor symptoms of Parkinson’s [1]. Because your brain is no longer producing enough dopamine, Levodopa acts as a “building block” that your brain converts into dopamine once it crosses the blood-brain barrier [1][2].

  • The “Bodyguard” (Carbidopa): If you took Levodopa alone, most of it would be converted to dopamine in your stomach and bloodstream, causing severe nausea. Carbidopa acts as a bodyguard, preventing Levodopa from breaking down until it safely reaches your brain [3][4].
  • Addressing “Levodopa Phobia”: Many patients worry that Levodopa “stops working” after a few years. Modern research shows this is not true. The drug does not lose its effect; rather, the underlying disease continues to progress, making it harder for the brain to store the dopamine provided [5].

Other Strategic Tools

While Levodopa is the heavy lifter, your doctor may use other classes of drugs to fine-tune your treatment.

The “Mimickers” (Dopamine Agonists)

Drugs like pramipexole and ropinirole don’t turn into dopamine; instead, they “trick” your brain by mimicking dopamine’s effects [6].

  • Impulse Control Disorders (ICDs): These drugs carry a unique risk for sudden, intense urges to gamble, shop, or eat compulsively [7][8]. Tell your doctor immediately if you or your family notice these changes.
  • Sleep Attacks: A critical side effect of these “mimickers” is excessive daytime sleepiness (EDS) and “sleep attacks”—falling asleep suddenly without warning [9][10]. This is reported in approximately 13% of patients and is extremely dangerous for driving or operating machinery [9].

The “Preservers” (MAO-B Inhibitors)

Your brain has an enzyme (MAO-B) that naturally breaks down dopamine. Drugs like rasagiline and selegiline block this enzyme, allowing your existing dopamine to stay in your system longer [11].

Managing “On” and “Off” Time

As the disease progresses, you may notice that your medication doesn’t last as long as it used to.

  • “Wearing Off”: When symptoms (like tremor or stiffness) return before it is time for your next dose [12][5].
  • Dyskinesia: Involuntary, “wriggling” movements that happen when there is too much dopamine stimulation [13]. This can often be managed with adjustments or medications like amantadine [14].

The Role of Diet in Treatment

Dietary protein can interfere with how your body absorbs Levodopa [15]. If you are experiencing “wearing off” or unpredictable medication effects, your doctor may suggest a Protein Redistribution Diet [16].

  • The Timing: The general rule is to take your Levodopa 30–60 minutes before a meal or 60–90 minutes after a meal [17].
  • Is it for everyone? No. Strict protein timing is usually only necessary for patients who have begun to experience “wearing off” or motor fluctuations [15]. If your medication works well regardless of when you eat, you do not need to follow these strict rules yet.
Phenomenon What it Feels Like Cause
Tremor Rhythmic shaking, usually at rest. Too little dopamine.
Dyskinesia Non-rhythmic, fluid “wriggling” movements. Peak levels of medication.
Wearing Off Sudden return of stiffness or slowness. Medication level dropping.
[12][13][5]

The best treatment strategy is one that maximizes your “On” time with the fewest side effects [18]. Small adjustments to timing or dosage can often make a big difference in your daily comfort.

Common questions in this guide

What is the difference between Levodopa and Carbidopa?
Levodopa is a "building block" that the brain converts into dopamine to manage motor symptoms. Carbidopa acts as a "bodyguard" that prevents Levodopa from breaking down in the bloodstream before it reaches the brain, reducing nausea and improving effectiveness.
Does Levodopa stop working after a few years?
Research shows that Levodopa does not stop working over time. Instead, the underlying Parkinson's disease progresses, making it harder for the brain to store and utilize the dopamine provided by the medication.
What is the difference between wearing off and dyskinesia?
"Wearing off" occurs when your medication's effects fade before it is time for your next dose, causing symptoms like stiffness or tremor to return. Dyskinesia refers to involuntary, wriggling movements caused by peak levels of dopamine stimulation.
What are the risks of taking dopamine agonists?
Dopamine agonists can cause impulse control disorders, which manifest as sudden, intense urges to gamble, shop, or eat compulsively. They can also cause "sleep attacks," where a patient falls asleep suddenly without warning.
Do I need to change my diet while taking Parkinson's medication?
Dietary protein can interfere with Levodopa absorption. If you experience "wearing off," your doctor may recommend taking medication 30–60 minutes before or 60–90 minutes after meals, but this is usually not necessary in early stages.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

How to Take Levodopa with Protein Meals for Parkinson's Why Does Parkinson's Medication Wear Off? Parkinson's Tremor vs Dyskinesia: What's the Difference? Do Parkinson's Drugs Cause Impulse Control Disorders?

Get notified when new evidence is published on Parkinson's Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my target daily dose of Levodopa, and how will we monitor for the onset of 'wearing off'?
  2. 2.If we start a dopamine agonist, what specific signs of 'impulse control disorders' should my family be looking for?
  3. 3.Is there a benefit to starting an MAO-B inhibitor now to delay the need for higher doses of Levodopa later?
  4. 4.How can we distinguish between my tremor and potential dyskinesia as my treatment progresses?
  5. 5.What is the current consensus on 'Levodopa-phobia' based on recent studies like the LEAP trial?
  6. 6.If I experience excessive daytime sleepiness on a dopamine agonist, what are our options for safely adjusting my dose?

References

References (18)
  1. 1

    l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice.

    Ueda S, Masukawa D, Koga M, Goshima Y

    Journal of pharmacological sciences 2016; (132(1)):109-112 doi:10.1016/j.jphs.2016.08.005.

    PMID: 27622543
  2. 2

    The role of L-DOPA in neurological and neurodegenerative complications: a review.

    Kulkarni SR, Thokchom B, Abbigeri MB, et al.

    Molecular and cellular biochemistry 2025; (480(10)):5221-5242 doi:10.1007/s11010-025-05324-w.

    PMID: 40488810
  3. 3

    Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis.

    Yoosefian M, Rahmanifar E, Etminan N

    Artificial cells, nanomedicine, and biotechnology 2018; (46(sup1)):434-446 doi:10.1080/21691401.2018.1430583.

    PMID: 29378432
  4. 4

    A Study for Therapeutic Treatment against Parkinson's Disease via Chou's 5-steps Rule.

    Lan J, Liu Z, Liao C, et al.

    Current topics in medicinal chemistry 2019; (19(25)):2318-2333 doi:10.2174/1568026619666191019111528.

    PMID: 31629395
  5. 5

    Animal models of l-dopa-induced dyskinesia in Parkinson's disease.

    Cenci MA, Crossman AR

    Movement disorders : official journal of the Movement Disorder Society 2018; (33(6)):889-899 doi:10.1002/mds.27337.

    PMID: 29488257
  6. 6

    Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.

    Carbone F, Djamshidian A

    CNS drugs 2024; (38(6)):443-457 doi:10.1007/s40263-024-01087-y.

    PMID: 38613665
  7. 7

    Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis.

    Garcia-Ruiz PJ

    Frontiers in neurology 2018; (9()):1041 doi:10.3389/fneur.2018.01041.

    PMID: 30574117
  8. 8

    Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study.

    Fusaroli M, Giunchi V, Battini V, et al.

    Psychiatry and clinical neurosciences 2023; (77(3)):160-167 doi:10.1111/pcn.13511.

    PMID: 36436204
  9. 9

    Sleep Attacks in Patients With Parkinson's Disease on Dopaminergic Medications: A Systematic Review.

    Yeung EYH, Cavanna AE

    Movement disorders clinical practice 2014; (1(4)):307-316 doi:10.1002/mdc3.12063.

    PMID: 30363881
  10. 10

    Sleep disturbances in Taiwanese patients with Parkinson's disease.

    Lin YY, Chen RS, Lu CS, et al.

    Brain and behavior 2017; (7(10)):e00806 doi:10.1002/brb3.806.

    PMID: 29075566
  11. 11

    Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.

    Tsunekawa H, Takahata K, Okano M, et al.

    Behavioural brain research 2018; (347()):350-359 doi:10.1016/j.bbr.2018.03.002.

    PMID: 29526790
  12. 12

    Medical Management and Prevention of Motor Complications in Parkinson's Disease.

    Aradi SD, Hauser RA

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2020; (17(4)):1339-1365 doi:10.1007/s13311-020-00889-4.

    PMID: 32761324
  13. 13

    New insights into pathogenesis of l-DOPA-induced dyskinesia.

    Zheng C, Zhang F

    Neurotoxicology 2021; (86()):104-113 doi:10.1016/j.neuro.2021.07.006.

    PMID: 34331976
  14. 14

    Efficacy and safety of oral amantadine in Parkinson's disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials.

    Rujirussawarawong S, Aungsumart S, Kasemsuk C, Limotai N

    BMJ neurology open 2025; (7(1)):e001115 doi:10.1136/bmjno-2025-001115.

    PMID: 40756069
  15. 15

    Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.

    Virmani T, Tazan S, Mazzoni P, et al.

    Journal of clinical movement disorders 2016; (3()):8 doi:10.1186/s40734-016-0036-9.

    PMID: 27231577
  16. 16

    Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.

    Wang L, Xiong N, Huang J, et al.

    Frontiers in aging neuroscience 2017; (9()):206 doi:10.3389/fnagi.2017.00206.

    PMID: 28701947
  17. 17

    To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson's disease.

    Rusch C, Flanagan R, Suh H, Subramanian I

    NPJ Parkinson's disease 2023; (9(1)):98 doi:10.1038/s41531-023-00541-w.

    PMID: 37355689
  18. 18

    Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.

    Stocchi F, Vacca L, Stirpe P, Torti M

    Expert opinion on drug metabolism & toxicology 2018; (14(12)):1189-1195 doi:10.1080/17425255.2018.1550483.

    PMID: 30479171

This guide explains Parkinson's medication strategies for educational purposes. Always consult your neurologist before changing your dosage, timing, or diet.